Prohibition of THCP, HHCPO, H4CBD and other cannabinoids
On May 22, 2024, France's Agence nationale de sécurité du médicament et des produits de santé (ANSM) amended its decision to classify cannabinoids formed from a benzo[c]chromene-type chemical nucleus. This modification excludes certain substances from this classification, under certain conditions.
New cannabinoids banned
In response to the risks and possible dependence associated with the use of certain cannabinoids, the ANSM has decided to classify new cannabinoids on the list of narcotics. This ban, effective from June 3, 2024, concerns :
Hemisynthetic cannabinoids
- H4-CBD
- H2-CBD
Synthetic cannabinoids with benzo[c]chromene core
- HHCPO (hexahydrocannabiphorol acetate)
- THCP (tetrahydrocannabiphorol)
- THCA (tetrahydrocannabinolic acid)
Synthetic cannabinoids
- 5F-Cumyl-Pegaclone (5F-SGT-151)
- Cumyl-CH-Megaclone (SGT-270)
- 7APAICA
- 5F-7APAICA
- Cumyl-P7AICA
- 5F-Cumyl-P7AICA
- BZO-Hexoxizid (MDA-19)
- BZO-Poxizid (5C-MDA-19)
Substances excluded from classification
The ANSM's recent decision excludes from classification certain substances present in very low concentrations. The cannabinoids concerned are:
- CBNA (cannabinolic acid) A precursor of CBN, already excluded from classification.
- THCVA (tetrahydrocannabivaric acid) and THCV (tetrahydrocannabivarin): Provided their content does not exceed 0.3%.
- THCA (tetrahydrocannabinolic acid): As long as their THC content complies with the 0.3% threshold laid down in the Decree of December 30, 2021.
Other alternatives?
We offer hydroponically grown CBD flowers, renowned for their remarkable effects. In addition, we offer THC cookies, syrups and candies, providing more intense sensations.
We are committed to providing a wide range of high quality CBD products, carefully selected and rigorously tested to ensure safety and compliance, our goal is to ensure our customers an optimal and risk-free CBD experience. What's more, we regularly add new products to our catalog for your enjoyment.
The ANSM's decision to modify the classification of certain cannabinoids reflects a desire to protect public health in the face of the risks associated with the consumption of these substances. For the CBD industry in France, it is crucial to comply with these new regulations, which is why we have withdrawn these products from our catalog.